Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Galecto ( (GLTO) ) has provided an update.
In January 2026, Galecto announced that it would present a new corporate slide deck to investors and analysts at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its recently acquired portfolio of potentially best‑in‑class therapies targeting mutant CALR‑driven myeloproliferative neoplasms following the acquisition of Damora Therapeutics. The materials outline a pipeline led by DMR‑001, a subcutaneous anti‑mutCALR monoclonal antibody with clinical proof‑of‑concept evidence in essential thrombocythemia and myelofibrosis, alongside additional mutCALR‑focused candidates (DMR‑002, DMR‑003) and small molecule GB3226 progressing toward IND and CTA milestones between 2026 and 2027, signaling a strategic push to establish a new standard of care and strengthen Galecto’s positioning in the MPN treatment landscape.
The most recent analyst rating on (GLTO) stock is a Hold with a $22.00 price target. To see the full list of analyst forecasts on Galecto stock, see the GLTO Stock Forecast page.
Spark’s Take on GLTO Stock
According to Spark, TipRanks’ AI Analyst, GLTO is a Neutral.
Score is held back primarily by weak financial performance (no revenue, losses, and cash burn with ongoing financing risk) despite improving burn trends and low debt. Corporate events are a key offset, with the Damora acquisition and sizable private investment extending runway, while technicals are mixed and valuation is constrained by unprofitability.
To see Spark’s full report on GLTO stock, click here.
More about Galecto
Galecto, Inc. operates in the biopharmaceutical industry, focusing on developing best‑in‑class biologic therapies for mutant calreticulin (mutCALR)-driven myeloproliferative neoplasms (MPNs), including essential thrombocythemia and myelofibrosis. Through its acquisition of Damora Therapeutics and collaboration with the Paragon Therapeutics team, the company is building a portfolio of mutCALR‑targeted antibodies and related modalities, such as subcutaneous monoclonal antibodies and T‑cell engagers, aimed at providing disease‑modifying and more convenient chronic treatment options across the full mutCALR MPN disease spectrum.
Average Trading Volume: 1,179,620
Technical Sentiment Signal: Buy
Current Market Cap: $32.54M
Find detailed analytics on GLTO stock on TipRanks’ Stock Analysis page.